The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.

Zamanian N, Imani H, Talebi S, Rahimlou M, Khosroshahi RA, Mohammadi H

European journal of pharmacology16 Jul 2025Cited by 11 (Europe PMC)

PMID40680981DOI10.1016/j.ejphar.2025.177966PepBankPUB-40680981

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, tirzepatide had a reported mean weight difference of -17.60 kg (95% CI: -32.15 to -2.95).
In plain wordsIn reviewed adults without diabetes with overweight or obesity, tirzepatide had a negative weight mean difference; the original comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseBody weight
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference
−17.6 kg
published MD; original comparison unstated
95% CI
−32.15 to −2.95 kg
published MD
Source sentences
Summary
Among these, tirzepatide demonstrated the greatest mean weight reduction (mean difference [MD]: -17.60 kg; 95 % confidence interval [CI]: -32.15 to -2.95), followed by semaglutide (MD: -11.85 kg; 95 % CI: -13.19 to -10.51).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search identified systematic reviews/meta-analyses of randomized controlled trials (RCTs) investigating GLP-1 RAs in non-diabetic adults with overweight/obesity.
Summary · context
Primary outcomes included weight/body mass index (BMI) changes, cardiometabolic parameters, and adverse events.
Summary · context
Fifteen systematic reviews and meta-analyses covering six GLP-1 RAs were included.
Report a problemFND-4068098101
02HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, semaglutide had a reported mean weight difference of -11.85 kg (95% CI: -13.19 to -10.51).
In plain wordsIn reviewed adults without diabetes with overweight or obesity, semaglutide had a negative weight mean difference; the original comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference
−11.85 kg
published MD; original comparison unstated
95% CI
−13.19 to −10.51 kg
published MD
Source sentences
Summary
Among these, tirzepatide demonstrated the greatest mean weight reduction (mean difference [MD]: -17.60 kg; 95 % confidence interval [CI]: -32.15 to -2.95), followed by semaglutide (MD: -11.85 kg; 95 % CI: -13.19 to -10.51).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search identified systematic reviews/meta-analyses of randomized controlled trials (RCTs) investigating GLP-1 RAs in non-diabetic adults with overweight/obesity.
Summary · context
Primary outcomes included weight/body mass index (BMI) changes, cardiometabolic parameters, and adverse events.
Summary · context
Fifteen systematic reviews and meta-analyses covering six GLP-1 RAs were included.
Report a problemFND-4068098102
03HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, liraglutide 3 mg had a reported mean weight difference of -4.59 kg (95% CI: -5.13 to -4.06).
In plain wordsIn reviewed adults without diabetes with overweight or obesity, liraglutide had a negative weight mean difference; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
3 mgAs given in this study (human).
Measurements
Mean difference
−4.59 kg
published MD; original comparison unstated
95% CI
−5.13 to −4.06 kg
published MD
Source sentences
Summary
Liraglutide (3 mg) showed moderate effects (MD: -4.59 kg; 95 % CI: -5.13 to -4.06).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search identified systematic reviews/meta-analyses of randomized controlled trials (RCTs) investigating GLP-1 RAs in non-diabetic adults with overweight/obesity.
Summary · context
Primary outcomes included weight/body mass index (BMI) changes, cardiometabolic parameters, and adverse events.
Summary · context
Fifteen systematic reviews and meta-analyses covering six GLP-1 RAs were included.
Report a problemFND-4068098103
04HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, semaglutide was associated with a BMI mean difference of -4.26 kg/m².
In plain wordsIn reviewed adults without diabetes with overweight or obesity, semaglutide had a negative BMI mean difference; the original comparison was unspecified.
Peptide
Semaglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference
−4.26 kg/m<sup>2</sup>
BMI
Source sentences
Summary
Semaglutide and liraglutide were also associated with significant reductions in BMI (MD: -4.26 kg/m² and -1.66 kg/m², respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search identified systematic reviews/meta-analyses of randomized controlled trials (RCTs) investigating GLP-1 RAs in non-diabetic adults with overweight/obesity.
Summary · context
Primary outcomes included weight/body mass index (BMI) changes, cardiometabolic parameters, and adverse events.
Summary · context
Fifteen systematic reviews and meta-analyses covering six GLP-1 RAs were included.
Report a problemFND-4068098104
05HumanSystematic reviewEfficacy outcome
In non-diabetic adults with overweight or obesity, liraglutide was associated with a BMI mean difference of -1.66 kg/m².
In plain wordsIn reviewed adults without diabetes with overweight or obesity, liraglutide had a negative BMI mean difference; the original comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference
−1.66 kg/m<sup>2</sup>
BMI
Source sentences
Summary
Semaglutide and liraglutide were also associated with significant reductions in BMI (MD: -4.26 kg/m² and -1.66 kg/m², respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search identified systematic reviews/meta-analyses of randomized controlled trials (RCTs) investigating GLP-1 RAs in non-diabetic adults with overweight/obesity.
Summary · context
Primary outcomes included weight/body mass index (BMI) changes, cardiometabolic parameters, and adverse events.
Summary · context
Fifteen systematic reviews and meta-analyses covering six GLP-1 RAs were included.
Report a problemFND-4068098105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms

Keywords